These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
216 related articles for article (PubMed ID: 32370858)
1. Comparison of Transatlantic Approaches to Lipid Management: The AHA/ACC/Multisociety Guidelines vs the ESC/EAS Guidelines. Singh M; McEvoy JW; Khan SU; Wood DA; Graham IM; Blumenthal RS; Mishra AK; Michos ED Mayo Clin Proc; 2020 May; 95(5):998-1014. PubMed ID: 32370858 [TBL] [Abstract][Full Text] [Related]
2. How effective are the ESC/EAS and 2013 ACC/AHA guidelines in treating dyslipidemia? Lessons from a lipid clinic. Barkas F; Milionis H; Kostapanos MS; Mikhailidis DP; Elisaf M; Liberopoulos E Curr Med Res Opin; 2015 Feb; 31(2):221-8. PubMed ID: 25418708 [TBL] [Abstract][Full Text] [Related]
3. The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. Ray KK; Kastelein JJ; Boekholdt SM; Nicholls SJ; Khaw KT; Ballantyne CM; Catapano AL; Reiner Ž; Lüscher TF Eur Heart J; 2014 Apr; 35(15):960-8. PubMed ID: 24639424 [TBL] [Abstract][Full Text] [Related]
4. Eligibility for PCSK9 inhibitors based on the 2019 ESC/EAS and 2018 ACC/AHA guidelines. Koskinas KC; Gencer B; Nanchen D; Branca M; Carballo D; Klingenberg R; Blum MR; Carballo S; Muller O; Matter CM; Lüscher TF; Rodondi N; Heg D; Wilhelm M; Räber L; Mach F; Windecker S Eur J Prev Cardiol; 2021 Mar; 28(1):59-65. PubMed ID: 33755142 [TBL] [Abstract][Full Text] [Related]
5. Implications of ACC/AHA Versus ESC/EAS LDL-C Recommendations for Residual Risk Reduction in ASCVD: A Simulation Study From DA VINCI. Vallejo-Vaz AJ; Bray S; Villa G; Brandts J; Kiru G; Murphy J; Banach M; De Servi S; Gaita D; Gouni-Berthold I; Kees Hovingh G; Jozwiak JJ; Jukema JW; Gabor Kiss R; Kownator S; Iversen HK; Maher V; Masana L; Parkhomenko A; Peeters A; Clifford P; Raslova K; Siostrzonek P; Romeo S; Tousoulis D; Vlachopoulos C; Vrablik M; Catapano AL; Poulter NR; Ray KK; Cardiovasc Drugs Ther; 2023 Oct; 37(5):941-953. PubMed ID: 35567726 [TBL] [Abstract][Full Text] [Related]
6. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines for cardiovascular disease prevention in a European cohort. Kavousi M; Leening MJ; Nanchen D; Greenland P; Graham IM; Steyerberg EW; Ikram MA; Stricker BH; Hofman A; Franco OH JAMA; 2014 Apr; 311(14):1416-23. PubMed ID: 24681960 [TBL] [Abstract][Full Text] [Related]
7. Population Effect of Differences in Cholesterol Guidelines in Eastern Europe and the United States. Lee JC; Zdrojewski T; Pencina MJ; Wyszomirski A; Lachacz M; Opolski G; Bandosz P; Rutkowski M; Gaciong Z; Wyrzykowski B; Navar AM JAMA Cardiol; 2016 Sep; 1(6):700-7. PubMed ID: 27434662 [TBL] [Abstract][Full Text] [Related]
8. ACC/AHA guidelines superior to ESC/EAS guidelines for primary prevention with statins in non-diabetic Europeans: the Copenhagen General Population Study. Mortensen MB; Nordestgaard BG; Afzal S; Falk E Eur Heart J; 2017 Feb; 38(8):586-594. PubMed ID: 28363217 [TBL] [Abstract][Full Text] [Related]
10. Statin Use in Primary Prevention of Atherosclerotic Cardiovascular Disease According to 5 Major Guidelines for Sensitivity, Specificity, and Number Needed to Treat. Mortensen MB; Nordestgaard BG JAMA Cardiol; 2019 Nov; 4(11):1131-1138. PubMed ID: 31577339 [TBL] [Abstract][Full Text] [Related]
11. Comparison of ACC/AHA and ESC Guideline Recommendations Following Trial Evidence for Statin Use in Primary Prevention of Cardiovascular Disease: Results From the Population-Based Rotterdam Study. Pavlovic J; Greenland P; Deckers JW; Brugts JJ; Kavousi M; Dhana K; Ikram MA; Hofman A; Stricker BH; Franco OH; Leening MJ JAMA Cardiol; 2016 Sep; 1(6):708-13. PubMed ID: 27439175 [TBL] [Abstract][Full Text] [Related]
12. New Recommendations and Revised Concepts in Recent Guidelines on the Management of Dyslipidemias to Prevent Cardiovascular Disease: the 2018 ACC/AHA and 2019 ESC/EAS Guidelines. Raygor V; Khera A Curr Cardiol Rep; 2020 Jul; 22(9):87. PubMed ID: 32647997 [TBL] [Abstract][Full Text] [Related]
13. Implications of the 2013 ACC/AHA cholesterol guidelines for adults in contemporary cardiovascular practice: insights from the NCDR PINNACLE registry. Maddox TM; Borden WB; Tang F; Virani SS; Oetgen WJ; Mullen JB; Chan PS; Casale PN; Douglas PS; Masoudi FA; Farmer SA; Rumsfeld JS J Am Coll Cardiol; 2014 Dec; 64(21):2183-92. PubMed ID: 25447259 [TBL] [Abstract][Full Text] [Related]
14. Guideline-based statin/lipid-lowering therapy eligibility for primary prevention and accuracy of coronary artery calcium and clinical cardiovascular events: The Multi-Ethnic Study of Atherosclerosis (MESA). Flueckiger P; Qureshi W; Michos ED; Blaha M; Burke G; Sandfort V; Herrington D; Yeboah J Clin Cardiol; 2017 Mar; 40(3):163-169. PubMed ID: 27859433 [TBL] [Abstract][Full Text] [Related]
15. Statin Eligibility for Primary Prevention of Cardiovascular Disease According to 2021 European Prevention Guidelines Compared With Other International Guidelines. Mortensen MB; Tybjærg-Hansen A; Nordestgaard BG JAMA Cardiol; 2022 Aug; 7(8):836-843. PubMed ID: 35793078 [TBL] [Abstract][Full Text] [Related]
16. The 2013 ACC/AHA cardiovascular prevention guidelines improve alignment of statin therapy with coronary atherosclerosis as detected by coronary computed tomography angiography. Pursnani A; Mayrhofer T; Ferencik M; Hoffmann U Atherosclerosis; 2014 Nov; 237(1):314-8. PubMed ID: 25299966 [TBL] [Abstract][Full Text] [Related]
17. What's next for dyslipidemia management? The 2013 ACC/AHA Guidelines, the NLA recommendations, and beyond. Waite LH; Phan YL; Spinler SA J Am Pharm Assoc (2003); 2016; 56(3):284-92. PubMed ID: 27156942 [TBL] [Abstract][Full Text] [Related]
18. Adoption of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline in Cardiology Practices Nationwide. Pokharel Y; Tang F; Jones PG; Nambi V; Bittner VA; Hira RS; Nasir K; Chan PS; Maddox TM; Oetgen WJ; Heidenreich PA; Borden WB; Spertus JA; Petersen LA; Ballantyne CM; Virani SS JAMA Cardiol; 2017 Apr; 2(4):361-369. PubMed ID: 28249067 [TBL] [Abstract][Full Text] [Related]
19. Comparison of the American College of Cardiology/American Heart Association and the European Society of Cardiology Guidelines for the Management of Patients With Valvular Heart Disease. Alame AJ; Karatasakis A; Karacsonyi J; Danek BA; Sorajja P; Gössl M; Garcia S; Jneid H; Kakouros N; Martinez-Parachini JR; Resendes E; Kalsaria P; Roesle M; Rangan BV; Banerjee S; Brilakis ES J Invasive Cardiol; 2017 Sep; 29(9):320-326. PubMed ID: 28420803 [TBL] [Abstract][Full Text] [Related]
20. Increases in statin eligibility to reduce cardiovascular risk according to the 2013 ACC/AHA cholesterol guidelines in the Africa Middle East region: a sub-analysis of the Africa Middle East Cardiovascular Epidemiological (ACE) study. Hamoui O; Omar MI; Raal FJ; Rashed W; Kane A; Alami M; Abreu P; Mashhoud W; Alsheikh-Ali AA BMC Cardiovasc Disord; 2019 Mar; 19(1):61. PubMed ID: 30876390 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]